Eisai and BioArctic Neuroscience Enter Exclusive Licensing Agreement with Novel Antibody Treatment for Alzheimer's Disease.
Publication Date: 04-DEC-07
Publication Title: JCN Newswires
Format: Online
Company: Eisai Company Ltd.

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Description

Tokyo, Japan, Dec 4, 2007 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) and BioArctic Neuroscience AB (Headquarter: Stockholm, Sweden, CEO: Par Gellerfors) announced today that on December 3, they signed an exclusive licence agreement for BAN2401, a novel humanized monoclonal antibody, which is being developed as a next-generation therapeutic treatment for Alzheimer's disease. Under the terms of the agreement Eisai obtains the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer's disease.

BAN2401 is the...

Access Full Article, Compliments of Goliath


More articles from JCN Newswires
Toyota Announces Groups Selected for FY2007 Environmental Activities G..., December 04, 2007
NEC Launches New 'Lui'-Branded Personal Solutions on Japanese Market T..., December 04, 2007
NEC Develops Technology to Further Enhance NGN Service Platform Throug..., December 04, 2007
NEC Develops Virtualization Technology to Assist Product Planning Deci..., December 04, 2007
OKI and Fujitsu Collaborate in Developing Next-Generation ATM Software..., December 04, 2007

Looking for additional articles?
Click here to search our database of over 3 million articles.